Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Operations (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash from Operations for 13 consecutive years, with 133460000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 27.73% to 133460000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 189553000.0 through Dec 2025, up 58.39% year-over-year, with the annual reading at 189553000.0 for FY2025, 58.39% up from the prior year.
  • Cash from Operations for Q4 2025 was 133460000.0 at Madrigal Pharmaceuticals, down from 79850000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 79850000.0 in Q3 2025, with the low at 149157000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 68906450.0, with a median of 63026500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations tumbled 93.26% in 2021, then surged 219.21% in 2025.
  • Over 5 years, Cash from Operations stood at 48051000.0 in 2021, then dropped by 21.78% to 58515000.0 in 2022, then tumbled by 36.6% to 79933000.0 in 2023, then plummeted by 30.72% to 104486000.0 in 2024, then fell by 27.73% to 133460000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 133460000.0, 79850000.0, and 47052000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.